Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
firzacorvir
- Development stage
- Discontinued
- Lead developer
- Assembly Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Firzacorvir** (also known as ABI-H2158) is a small molecule cyclic sulfamide **HBV core protein inhibitor** developed by Assembly Biosciences for the treatment of **chronic hepatitis B**. It modulates HBV core protein allosterically, disrupting viral capsid assembly and genome packaging, with potent pan-genotypic anti-HBV activity (EC50 <1 μM). Development reached **Phase 2** trials but was **discontinued** due to hepatotoxicity concerns.
- Other names
- ABI-H-2158ABI-H2158ABI-H 21582158
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on firzacorvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on firzacorvir.